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 Abstract 
  Background:  Apelin is a selective endogenous ligand of the APJ receptor, which genetically has 
closest identity to the angiotensin II type 1 receptor (AT-1). The effects of the apelin/APJ system 
on renal fibrosis still remain unclear.   Methods:   We examined the effects of the apelin/APJ sys-
tem on renal fibrosis during AT-1 blockade in a mouse unilateral ureteral obstruction (UUO) 
model.   Results:   We obtained the following results: (1) At UUO day 7, mRNA expressions of ape-
lin/APJ and phosphorylations of Akt/endothelial nitric oxide synthase (eNOS) in the UUO kidney 
were increased compared to those in the nonobstructed kidney. (2) AT-1 blockade by the treat-
ment with losartan resulted in a further increase of apelin mRNA as well as phosphorylations of 
Akt/eNOS proteins, and this was accompanied by alleviated renal interstitial fibrosis, decreased 
myofibroblast accumulation, and a decreased number of interstitial macrophages. (3) Blockade 
of the APJ receptor by the treatment with F13A during losartan administration completely ab-
rogated the effects of losartan in the activation of the Akt/eNOS pathway and the amelioration 
of renal fibrosis. (4) Inhibition of NOS by the treatment with L-NAME also resulted in a further 
increase in renal fibrosis compared to the control group.  Conclusion:  These results suggest that 
increased nitric oxide production through the apelin/APJ/Akt/eNOS pathway may, at least in 
part, contribute to the alleviative effect of losartan in UUO-induced renal fibrosis. 
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 Introduction 
  Apelin is a selective endogenous ligand of the G protein-coupled receptor APJ and was 
originally isolated from bovine stomach extracts  [1, 2] . The APJ receptor was originally iden-
tified as a gene with closest identity to the angiotensin II type 1 receptor (AT-1) and was kept 
‘orphan’ until the identification of apelin   [1]  . Both apelin and the APJ receptor were found 
to be distributed in a wide variety of tissues including the central nervous system, heart, 
lungs, and kidneys  [3–7] , and the apelin/APJ system has been shown to have relevant roles in 
the regulation of cardiovascular, gastrointestinal, and immune functions, bone physiology, 
fluid homeostasis, and embryonic development of the cardiovascular system  [8–10] . Interest-
ingly, in spite of a high homology between the APJ and the AT-1 receptors, and similar pat-
terns of tissue expression for both receptors, previous reports showed opposing actions be-
tween the apelin/APJ system and the angiotensin II (Ang II)/AT-1 system in a number of 
physiologic and pathophysiologic settings   [11–17]  . Apelin mediates opposing actions to Ang 
II on vascular tone, blood pressure, and fluid homeostasis   [11–17]  . Furthermore, recent re-
ports showed antifibrotic actions of apelin in the cardiovascular system that counteracts to 
Ang II   [17, 18]  . However, the role of apelin in renal fibrosis, where the Ang II/AT-1 system 
has been proved to have critical roles   [19, 20]  , has not yet been elucidated. Additionally, pre-
vious studies have shown that apelin acts to increase nitric oxide (NO) production in endo-
thelial cells   [21]  , and NO exerts tissue-protective effects in several pathological settings in-
cluding renal fibrosis induced by unilateral ureteral obstruction (UUO) that is a nonimmu-
nological model of progressive renal fibrosis   [22, 23]  . Thus, in this study, we used a mouse 
UUO model and studied the role of apelin in renal fibrosis during the administration of an-
giotensin receptor blocker, and also the role of NO production on these changes.
  Materials  and  Methods 
 Experimental  Protocol 
 Experiments were performed on male C57BL/6 mice (10–12 weeks, 20–24 g). These mice 
were subjected to a complete UUO as previously described (day 0)  [24] . Briefly, under sodium 
pentobarbital anesthesia, the middle portion of the left ureter was ligated and cut between 
the two ligated points. The mice were sacrificed at day 7 after surgery, and the obstructed 
kidneys were harvested and subjected to the studies. The mice were divided to a total of four 
groups as follows: (1) control, (2) losartan (a specific AT-1 receptor antagonist), (3) losartan 
+ F13A (a specific APJ receptor antagonist), and (4) losartan +   L -NAME [a NO synthase 
(NOS) inhibitor]. Mice of the losartan and   L -NAME treatment groups were fed water con-
taining 0.1 mg/ml (30 mg/kg per day) losartan (Merck & Co. Inc., Rahway, N.J., USA) and/
or 0.1 mg/ml   L -NAME (Tocris Cookson Inc., Ellisville, Mo., USA) starting 3 days before 
UUO until day 7 after surgery. Mice in the F13A treatment group were injected intraperito-
neally once a day with a daily dose of 150     g/kg F13A (Phoenix Pharmaceuticals Inc., Bur-
lingame, Calif., USA) diluted in 0.4 ml saline or saline only as controls. The systolic blood 
pressure of the mice was measured by the tail-cuff method using MK-2000ST (Muromachi 
Kikai, Inc., Tokyo, Japan) at day 0, day 3, and day 7 after UUO. The experimental protocols 
were performed according to the regulations of the Kyoto Prefectural University of Medicine 
Animal Care Committee.
  R T- P C R   A n a l y s i s  
 Total RNA was isolated from the UUO kidneys using Sepasol (R)-RNA I Super (Nacalai 
Tesque, Inc., Kyoto, Japan), and RT-PCR for apelin, APJ receptor, and GAPDH mRNA was 41
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performed as previously described   [16]  . In brief, the sample RNA was reverse-transcribed 
using a High Capacity cDNA Archive kit (Applied Biosystems, Foster City, Calif., USA). PCR 
amplification was performed using Power SYBR     Green PCR Master Mix (Applied Biosys-
tems). The forward and reverse primers for mouse apelin mRNA were 5   -CGAGTTGC -
AGCATGAATCTGAG-3     and 5   -TGTTCCATCTGGAGGCAACATC-3   , respectively, and 
those for mouse APJ receptor were 5   -GTGGCCAATGCTCGGCTAA-3    and 5   -TGG AA-
CGGAACACCATGACAG-3   , whereas those for GAPDH were 5   -TG TG TCC GT CG TG GA-
TCTGA-3     and 5   -TTGCTGTTGAAGTCGCAGGAG-3  .
  Western  Blot  Analysis 
  Western blot analysis was performed as previously described   [17]  . In brief, the obstruct-
ed kidneys were lysed in lysis buffer containing 20 m  M  Tris-HCl pH 8.0, 150 m  M  NaCl, 1 m  M  
EDTA, 100 m  M  NaF, 1 m  M  Na 3 VO 4 , and 1% proteinase inhibitor (Sigma-Aldrich Japan K.K., 
Tokyo, Japan). Lysates were centrifuged at 10,000   g   for 10 min, and supernatants (30    g  pro-
tein/lane) were separated by SDS-PAGE on a 10% acrylamide gel. Gels were electroblotted 
onto a nitrocellulose membrane (GE Healthcare UK Ltd., Little Chalfont, UK). The mem-
branes were blocked with 2% nonfat dry milk and incubated with either polyclonal rabbit 
anti-phospho-endothelial NOS (p-eNOS; Cell Signaling Technology Inc., Danvers, Mass., 
USA), polyclonal rabbit anti-phospho-Akt (p-Akt; Cell Signaling Technology Inc.), or poly-
clonal goat anti-    -tubulin (Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA) over-
night at 4    °    C. The membranes were then incubated with horseradish peroxidase-conjugated 
goat anti-rabbit IgG (Cell Signaling Technology Inc.) to detect p-eNOS and p-Akt, and with 
horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology Inc.) to 
detect     -tubulin, developed with the ECL Plus Detection System (GE Healthcare UK Ltd.), 
and captured on X-ray film. The signals were scanned and semiquantitated using the Image 
J program.
  Histological  Study 
  For histological examinations, the kidneys were fixed with 4% buffered paraformalde-
hyde for 6 h, embedded in paraffin, and sectioned transversely with a thickness of 4    m.  By 
immunostaining for     -smooth muscle actin (    -SMA), sections were incubated with mono-
clonal mouse anti-human     -SMA (DAKO, Carpinteria, Calif., USA), according to the man-
ufacturer’s protocol   [25]  . To detect infiltrating macrophages, sections were incubated with 
monoclonal rat anti-mouse F4/80 (Selotec, Oxford, UK) for 1 h at room temperature, fol-
lowed by standard ABC immunostaining using ABC-alkaline phosphatase kit (Vector, Bur-
lingame, Calif., USA)   [24]  . A standard point-counting method was used to quantitate the 
collagen fractional volume in the renal cortical interstitium on Masson’s trichrome-stained 
sections (magnification  ! 400), as previously described  [24] . The index of the interstitial col-
lagen fractional volume was defined as the number of trichrome-positive points in every 
1,000 points evaluated. The expression of   -SMA in the cortical interstitial area was assessed 
semiquantitatively by immunoreactivity for     -SMA, as previously described   [25]  . The num-
ber of infiltrating macrophages was determined by enumerating F4/80-positive cells within 
the cortical interstitium in 10 randomly selected cortical fields under magnification (  ! 400), 
and the numbers were averaged for each field   [24]  .
   Statistical  Analysis 
    Data are presented as means   8   SEM. Statistical analysis was performed by ANOVA for 
multiple comparison analysis. Statistical significance was defined as p   !   0.05.42
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  R e s u l t s  
  mRNA Expressions of Apelin and APJ Receptor in the UUO Kidneys 
    The mRNA expressions of apelin and APJ receptor in the UUO kidneys were both sig-
nificantly increased at day 7 after UUO compared with those in nonobstructed kidneys 
(NOB) at day 0 (the ratio to GAPDH mRNA, apelin: 0.37   8   0.04 vs. 0.65   8   0.12, p   !   0.05,
n = 6 in each group; APJ receptor: 0.13   8   0.01 vs. 0.97   8   0.03, p   !   0.01, n = 6) (  fig. 1  a, b). 
Treatment with losartan further significantly enhanced the expression of apelin mRNA com-
pared with that in the control group at day 7 after UUO (0.90   8   0.03, p   !   0.05 vs. control 
group, n = 6) (  fig. 1  a); however, no significant change was observed in the expression of APJ 
receptor with losartan treatment (0.98  8  0.03, not signficant vs. control group, n = 6) ( fig. 1 b).
  Blood  Pressure 
 No significant difference was observed in the systolic blood pressure between the groups 
either at day 0 (before UUO), day 3, or day 7 after UUO (control; losartan; losartan + F13A; 
losartan +   L -NAME groups, respectively; day 0: 108   8   4; 97   8   2; 96   8   2; 98   8   4 mm Hg, 
not significant among groups; day 3: 97  8  3; 94  8  1; 97  8  2; 95  8  1 mm Hg, not significant 
among groups; day 7: 102  8  3; 94  8  2; 95  8  2; 93  8  6 mm Hg, not significant among groups; 
n = 9 in the control group, n = 8 in the losartan group, n = 6 in the losartan + F13A and losar-
tan +   L -NAME groups).
    p-eNOS and p-Akt Protein Expressions 
  The protein expressions of p-eNOS and p-Akt in the UUO kidneys were assessed by 
Western blotting and were both increased at day 7 after UUO compared with those in NOB 
at day 0 (the ratio to     -tubulin protein, p-eNOS: 0.20   8   0.02 vs. 0.72   8   0.11, p   !   0.01, n = 6 
in each group; p-Akt: 0.13   8   0.02 vs. 0.41   8   0.03, p   !   0.01, n = 6 in each group). Treatment 
with losartan further enhanced phosphorylations of both of these proteins (p-eNOS: 2.74  8  
0.18, p   !   0.01 vs. control group, n = 6; p-Akt: 0.83   8   0.07, p   !   0.01 vs. control group, n = 6), 
and cotreatment with F13A, a APJ receptor antagonist, significantly suppressed the effects 
of losartan on the expressions of both of these proteins (p-eNOS: 0.81   8   0.12, p   !   0.01 vs. 
losartan group, n = 6; p-Akt: 0.43   8   0.03, p   !   0.01 vs. losartan group, n = 6) (  fig. 2  a–c).
  Interstitial  Fibrosis 
  Treatment with losartan resulted in a significant decrease in the interstitial collagen in-
dex at day 7 after UUO compared with the control group (64   8   3 vs. 41   8   4/1,000 points,
  Fig. 1.  The mRNA expressions of 
apelin and APJ receptor in the 
UUO kidneys. Total RNA was 
extracted from obstructed kid-
neys at day 7 after UUO and 
fr o m  N O B.  mRN A  exp r ess i o ns  
of apelin (  a ) and APJ receptor (  b ) 
were assessed by real-time RT-
PCR. Data are expressed as 
means   8   SEM.   *  p   !   0.05;   *  *  p   !  
0.01. NS = Not significant. 43
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p  !  0.01, n = 9 in the control group and n = 8 in the losartan group). However, treatment with 
both losartan + F13A and losartan +   L -NAME resulted in significant increases in the inter-
stitial collagen index compared to mice treated with losartan only, and also compared to 
control mice receiving no treatment (83  8  3 in the losartan + F13A group, p  !  0.01 vs. losar-
tan group, p   !   0.05 vs. control group, n = 6; 84   8   3 in the losartan +   L -NAME group, p   !  
0.01 vs. losartan group, p   !   0.05 vs. control, n = 6) (  fig. 3  a, b).
  Myofibroblast  Accumulation 
  The degree of interstitial myofibroblast accumulation assessed by immunostaining for 
   -SMA was significantly lower in mice treated with losartan compared to that in the control 
group at day 7 after UUO (    -SMA score; 1.88   8   0.09 vs. 1.32   8   0.08, p   !   0.01, n = 9 in the 
control group and n = 8 in the losartan group). However, treatment with both losartan + 
F13A and losartan +   L -NAME resulted in significant increases in the interstitial myofibro-
blast accumulation compared with mice treated with losartan only, and also compared to 
control mice receiving no treatment (2.38   8   0.14 in the losartan + F13A group, p   !   0.01 vs. 
losartan group, p   !   0.05 vs. control group, n = 6; 2.43   8   0.08 in the losartan +   L -NAME 
group, p   !   0.01 vs. losartan group, p   !   0.05 vs. control group, n = 6) (  fig. 3  a, c).
  Interstitial  Macrophage  Infiltration 
  The number of F4/80-positive macrophages infiltrating to the interstitium was signifi-
cantly decreased in mice treated with losartan compared to that in the control group at day 
7 after UUO (24.0   8   1.2 vs. 17.6   8   1.5/ !  400 field, p   !   0.01, n = 9 in the control group and
n = 8 in the losartan group). However, treatment with both losartan + F13A and losartan +   
  L -NAME resulted in significant increases in the number of interstitial macrophages com-
pared with mice treated with losartan only, and also compared to control mice receiving no 
treatment (34.4   8   1.5 in the losartan + F13A group, p   !   0.01 vs. losartan group, p   !   0.01 vs. 
control group, n = 6; 36.0  8  1.6 in the losartan +   L -NAME group, p  !  0.01 vs. losartan group, 
p   !   0.01 vs. control, n = 6) (  fig. 3  a, d).
  Fig. 2.   p-eNOS and p-Akt protein expressions in the UUO kidneys. Whole kidney lysates from obstruct-
ed kidneys at day 7 after UUO and from NOB were examined for p-eNOS and p-Akt protein expressions 
by Western blot analysis (  a  ), and quantitatively analysed as the ratio to     -tubulin protein for p-eNOS (  b ) 
and p-Akt (  c  ). Data are expressed as means   8   SEM.   *  *  p   !   0.01. 44
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  Fig. 3.   Histological assessment of interstitial fibrosis, myofibroblast accumulation, and macrophage in-
filtration in the UUO kidneys. Masson’s trichrome staining and immunohistochemical demonstration 
of myofibroblasts with anti-    -SMA antibody, and of macrophages with anti-F4/80 antibody in control 
mice, in mice treated with losartan, and in mice treated with losartan + F13A at day 7 after UUO (  a ). 
Original magnification,  ! 400. Quantitative analysis of interstitial collagens assessed by the point-count-
ing method on Masson’s trichrome-stained sections (  b  ), of interstitial myofibroblast accumulation as-
sessed by     -SMA score (  c  ), and of the number of F4/80-positive macrophages infiltrating to the intersti-
tium (  d ) in control mice, in mice treated with losartan, in mice treated with losartan + F13A, and in mice 
treated with losartan +   L -NAME at day 7 after UUO. Data are expressed as means   8   SEM.   *  p   !   0.05; 
  *  *  p   !   0.01. NS = Not significant. 45
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  Discussion 
 In this study, we first examined the mRNA expressions of apelin and APJ receptor in the 
UUO kidneys and found that both apelin and APJ receptor mRNAs were upregulated at day 
7 after UUO. Furthermore, treatment with losartan resulted in a significant increase in the 
apelin mRNA expression, but not in that of the APJ receptor, compared with the control 
group at day 7 after UUO. These results suggest that the apelin/APJ system is upregulated in 
the UUO kidney compared with that in the NOB, and that the blockade of the AT-1 receptor 
results in further upregulation of apelin production in this model. These results are consis-
tent with previous reports showing a counter-regulatory role of the apelin/APJ and Ang II/
AT-1 systems   [11–17]  . One of the major actions of apelin via the APJ receptor is eNOS pro-
duction through the Akt/eNOS pathway which causes vasodilation   [21]   and may exert anti-
fibrotic tissue-protective effects in the UUO kidney   [22, 23]  . Thus, we next examined the 
phosphorylation of the Akt/eNOS pathway in the UUO kidney as well as the pathological 
changes related to renal interstitial fibrosis.
    Our results indicate that phosphorylations of both Akt and eNOS are significantly in-
creased in the UUO kidney compared with NOB at day 7 after UUO, and treatment with 
losartan results in marked increases in both p-Akt and p-eNOS proteins compared with the 
control group. F13A is a compound generated by substituting carboxyl-terminal phenylala-
nine in apelin-13 with alanine residue, and it has been proved to act as a specific antagonist 
of the APJ receptor   [26, 27]  . When mice were cotreated with losartan + F13A, the effects of 
losartan on the activation of the Akt/eNOS pathway were completely abrogated. These re-
sults suggest that upregulation of apelin production by the treatment with losartan contrib-
utes to the activation of the Akt/eNOS pathway in the UUO kidney. Additionally, although 
treatment with losartan resulted in alleviated renal interstitial fibrosis, decreased myofibro-
blast accumulation, and a decreased number of macrophages infiltrating to the interstitium 
compared with the control group, cotreatment with losartan + F13A completely abrogated 
all these effects of losartan and even significantly increased the degrees of renal fibrosis, 
myofibroblast accumulation, and the number of infiltrating macrophages compared with 
the control group. These results suggest that the alleviative effect of losartan in renal fibrosis 
in the UUO kidney is, at least in part, due to the action of apelin via the APJ receptor. Fur-
thermore, cotreatment with losartan +   L -NAME, a NOS inhibitor, also completely abrogated 
the effects of losartan and significantly increased the degrees of renal fibrosis, myofibroblast 
accumulation, and the number of infiltrating macrophages to a level comparable with losar-
tan + F13A treatment. These results suggest that increased NO production through the ape-
lin/APJ/Akt/eNOS pathway may, at least in part, contribute to the alleviative effect of losar-
tan in UUO-induced renal fibrosis.
  The antifibrotic and antiapoptotic effects of NO on the UUO kidney have been reported 
in several previous studies  [22, 23] . Dietary arginine supplementation has been shown to im-
prove renal damage including fibrosis and apoptosis in the UUO kidney without affecting 
renal blood flow and glomerular filtration rate, suggesting increased NO bioavailability  [23] . 
Also in our study, the systolic blood pressures of mice of each experimental group did not 
significantly differ, and increased NO production may possibly exert antifibrotic tissue-pro-
tective effects presumably by improving microcirculation and acting as antiapoptotic in the 
UUO kidney.
    Although the mechanism for the counter-regulatory action of the apelin/APJ system to 
the renin-angiotensin system is still unclear, growing evidence indicates that apelin mediates 
opposing actions to Ang II. Apelin attenuates Ang II-induced vasoconstriction through both 
the NO-dependent and NO-independent pathway   [12, 13]  . Besides, in the kidney, apelin has 
glomerular hemodynamic functions that oppose to Ang II through the release of NO   [16]  . A 46
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recent report also showed that apelin inhibits Ang II signaling pathways including extracel-
lular signal-regulated kinase phosphorylation and transcriptional regulation of multiple tar-
gets, and that the AT-1 and APJ receptors can physically associate on the cell membrane by 
forming heterodimers and may influence downstream signaling in a stoichiometric fashion 
 [15] . Furthermore, protective effects of apelin in cardiovascular fibrosis have also been shown 
more recently in a model of Ang II-induced cardiovascular fibrosis  [18]  and during the treat-
ment with an angiotensin receptor blocker   [17]  . However, our study is the first report that 
shows the role of the apelin/APJ system on the alleviative effect of renal fibrosis during in-
hibition of the Ang II/AT-1 system.
  In summary, we have shown, for the first time, that pharmacological blockade of the Ang 
II/AT-1 system upregulates the apelin/APJ system, and that the apelin/APJ system contrib-
utes to the alleviative effect of renal fibrosis on the UUO kidney via activation of the Akt/
eNOS pathway. Further studies regarding the role of apelin/APJ during the evolution of renal 
fibrosis and the regulatory mechanism of the apelin/APJ and renin-angiotensin systems are 
considered necessary. Nevertheless, our study provides insights into the role of Ang II inhi-
bition and, more importantly, raises the possibility of therapeutic options targeting apelin/
APJ as well as the renin-angiotensin system for the treatment of renal fibrosis.
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